HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

496.758

-15.630-3.05%

Number of Gainers:6

Number of Losers:25

Number of Flat:2

PE:- -

High:512.373

Open:512.373

Low:495.812

Close:512.388

Volume:95.41M

Turnover:2.18B

Market Cap:315.16B

Float Cap:281.17B

Loading ...

Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round

THOMSON REUTERS

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal

BOC International sees pharma sector earnings recovery as industry enters a reversal cycle

HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth

HK-Listed HBM Climbs on Initiating Next Phase of Asthma Drug Study

Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378

Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

THOMSON REUTERS

Genfleet-B Completes Share Buyback Worth HK$1.54 Million

The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines

ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308

Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8

Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":496.75812,"timestamp":1789027721934,"preClose":512.3882,"halted":0,"volume":95412163,"delay":0,"changeRate":-0.030504,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-15.630066,"latestTime":"09-10 16:00:00","open":512.3731,"high":512.3731,"low":495.81204,"amount":2180840440,"amplitude":0.032321,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"pbRate":3.809281,"peRate":169.439728,"turnoverRate":0.003564,"increases":5,"decrements":26,"flats":1,"marketCap":315159581920,"floatMarketCap":281174468760},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":512.3731,"amplitude":0.032321,"preClose":512.3882,"low":495.81204,"pbRate":"3.809281","latestPrice":496.75812,"volume":95412163,"delay":0,"open":512.3731,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":515.473,"twentyDayClose":536.134,"sixtyDayClose":437.19,"secType":"PLATE","market":"HK","turnoverRate":0.003564,"peRate":169.439728,"marketCap":315159581920,"floatMarketCap":281174468760,"timestamp":1789027721934,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666976587","title":"Hbm Holdings - Solstice Oncology Launches $225 Mln Series a Financing Round","url":"https://stock-news.laohu8.com/highlight/detail?id=2666976587","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666976587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952256,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1574","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666582914","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase Cancellation at HKD 20.82-21.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2666582914","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666582914?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:45","pubTimestamp":1788950714,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase cancellation at HKD 20.82-21.38Zylox-Tonbridge filed a next-day disclosure return reporting an on-market buyback of 53,500 H s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL3Z32VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","BK1583","02190","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782105","title":"UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782105","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143782105?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:03","pubTimestamp":1788940980,"startTime":"0","endTime":"0","summary":"UBS has released a research report indicating that first-half results among Chinese pharmaceutical stocks were mixed, with five of the nine rated companies exceeding market expectations. These...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","01530","03692","BK1589","BK1593","IE00BZ08YR35.GBP","BK1515","IE00BZ08YT58.USD","BK1161","BK1521","IE00B3M56506.USD","BK1191","03933","01477","HK0000165453.HKD","02096","BK1583","01177","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144997108","title":"Dizal Pharmaceutical's Birelentinib Shows Promise in Lymphoma Study Published in Blood Cancer Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=1144997108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144997108?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:00","pubTimestamp":1788940815,"startTime":"0","endTime":"0","summary":"Dizal Pharmaceutical Co., Ltd. (688192.SH) has announced that the results of its Phase II clinical study, TAI-SHAN9, evaluating the company's first-in-class, fully brain-penetrant, non-covalent...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688192","159938","BK1161","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112577285","title":"BOC International sees pharma sector earnings recovery as industry enters a reversal cycle","url":"https://stock-news.laohu8.com/highlight/detail?id=1112577285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112577285?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924637,"startTime":"0","endTime":"0","summary":"The pharmaceutical sector's interim reports for the first half of 2026 have been fully released, revealing resilient overall growth with structural improvements continuing to unfold, according to BOC...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1161","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159200143","title":"HK Stock Market Alert | VIVA BIOTECH (01873) Surges Over 5% as Two New CDMO Commercial Projects from Langhua Pharma Drive Key Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=1159200143","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159200143?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:30","pubTimestamp":1788924624,"startTime":"0","endTime":"0","summary":"VIVA BIOTECH (01873) surged more than 5% in Thursday's trading session, last up 5.17% at HK$1.425 with turnover reaching HK$7.54 million.According to the company's recently disclosed first-half...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDMO","KCAI","BK1141","VXUS","01873","BK1574","BK1576","BK1191","01477","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666033309","title":"HK-Listed HBM Climbs on Initiating Next Phase of Asthma Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2666033309","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666033309?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:47","pubTimestamp":1788922062,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed HBM climbs on initiating next phase of asthma drug study** Shares of HBM Holdings2142.HKclimb 3.7% to HK$15.09** Therapeutics developer says its partner Windward Bio AG reportedpositive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N45102M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02142","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141984241","title":"Hong Kong Stock Market Movers: HBM Holdings-B (02142) Climbs Over 4% in Morning Session After Positive Asthma Trial Results and Stock Connect Inclusion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141984241","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141984241?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:42","pubTimestamp":1788921769,"startTime":"0","endTime":"0","summary":"Shares of HBM Holdings-B (02142) surged more than 4% during Tuesday's morning trading session, with the stock last changing hands at HK$15.23, up 4.67%, on turnover of approximately HK$59.8...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1583","BK4585","BK1574","BK1161","KCAI","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309337","title":"Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309337","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309337?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:03","pubTimestamp":1788919398,"startTime":"0","endTime":"0","summary":"BUZZ-Ascletis hits 4-week high on initiating US Phase I study on obesity drug** Shares of Ascletis Pharma Inc1672.HKclimb 5.6% to HK$10.75, their highest since August 13** Stock on track for biggest one-day pct gain since August 7** Pharmaceutical products producer says it hasinitiateda U.S. Phase I study of ASC36 oral tablets for treatment of obesity after receiving Investigational New Drug clearance from the U.S. Food and Drug Administration** ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in non-human primates - co** YTD, stock down 7.3%, while Hang Seng Biotech Index.HSBIOup 10.7%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL1N451020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186275720","title":"How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1186275720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186275720?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:41","pubTimestamp":1788910867,"startTime":"0","endTime":"0","summary":"Traditional Chinese Medicine (TCM) has long been built on the accumulated wisdom of generations of physicians. However, when measured against the rigorous standards of modern medicine, the industry...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4159","MEDX","BK1161","RCT","IBBQ","BK1574","LNGR","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136667600","title":"TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1136667600","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136667600?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:26","pubTimestamp":1788873985,"startTime":"0","endTime":"0","summary":"TYK Medicines-B (02410) has announced that its Chairman, Executive Director and President, Dr. Wu Yusheng, has informed the company of his recent share purchases in the open market. Dr. Wu may...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","02410","BK1161","BK1574","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167922243","title":"HBM Holdings' Asthma Therapy Shows Promising Phase II Results and Moves to Phase III","url":"https://stock-news.laohu8.com/highlight/detail?id=1167922243","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167922243?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:58","pubTimestamp":1788872333,"startTime":"0","endTime":"0","summary":"HBM HOLDINGS-B (02142) has announced that its partner, Windward Bio AG, has reported positive interim results from the Phase II portion of the POLARIS-1 clinical trial evaluating HBM9378/WIN378 for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154956841","title":"Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1154956841","media":"Deep News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154956841?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:52","pubTimestamp":1788871964,"startTime":"0","endTime":"0","summary":"Chengdu Easton Biopharmaceuticals Co.,Ltd. (SSE: 688513) announced on September 8 that it will take part in the Science and Technology Innovation Board's collective earnings briefing for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","BK1161","BK0239","06978","KSTR","BK1574","IBBQ","159992","688513","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320273","title":"HBM Says Partner Windward Bio Starts Phase 3 Asthma Trial of Twice-Yearly TSLP Antibody Hbm9378/win378","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320273","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320273?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869907,"startTime":"0","endTime":"0","summary":"HBM says partner Windward Bio starts Phase 3 asthma trial of twice-yearly TSLP antibody HBM9378/WIN378HBM Holdings highlighted positive interim Phase 2 asthma results for HBM9378/WIN378, an ultra-long","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL4WknG1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320213","title":"Hbm9378/Win378, an Ultra-Long-Acting Antibody Targeting Tslp, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320213","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320213?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:17","pubTimestamp":1788869848,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA60HVBV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02142","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126663144","title":"Genfleet-B Completes Share Buyback Worth HK$1.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1126663144","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126663144?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:11","pubTimestamp":1788869514,"startTime":"0","endTime":"0","summary":"On September 8, 2026, GENFLEET-B (02595) announced that it had repurchased a total of 57,000 shares at a cost of HK$1.5418 million.The buyback was executed in accordance with the company's existing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595","BK1574","BK1515","159938","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190517580","title":"The AI Drug Discovery Sector Enters Its Value-Realization Phase, Unlocking Fresh Growth Avenues for Innovative Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=1190517580","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190517580?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:10","pubTimestamp":1788869456,"startTime":"0","endTime":"0","summary":"The AI-driven pharmaceutical industry has moved past its early-stage concept hype, with validation levels steadily climbing. The narrative has shifted from algorithmic promise to tangible pipeline...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","BK1191","159992","IBBQ","LNGR","QTOC","VTHR","MEDX","06978","ARTY","CHAT","BK1574","AIPO","01477","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141807270","title":"ALEBUND-B Wins US FDA Nod to Start Trial of Novel IgA Nephropathy Drug AP308","url":"https://stock-news.laohu8.com/highlight/detail?id=1141807270","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141807270?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:06","pubTimestamp":1788869176,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","IBBJ","BK1191","09637","BK1515","PSYK","BK1161","159938","MDTX","159151","09939","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175433190","title":"Alphamab-B Repurchases 220,000 Shares for HK$1.85 Million on September 8","url":"https://stock-news.laohu8.com/highlight/detail?id=1175433190","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175433190?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:28","pubTimestamp":1788866893,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that it spent HK$1.8499 million to buy back 220,000 shares on September 8, 2026.The repurchase reflects the company's ongoing commitment to enhancing shareholder value through strategic capital management initiatives.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323327","title":"Alphamab Oncology Files HKEX Next-Day Return Disclosing Share Repurchase at HKD 8.41","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323327","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323327?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866733,"startTime":"0","endTime":"0","summary":"Alphamab Oncology files HKEX next-day return disclosing share repurchase at HKD 8.41Alphamab Oncology repurchased 220,000 shares on Sept. 8 for treasury, no cancellations disclosed.Buyback price range","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8Tygqr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":2,"totalSize":269,"code":"91000000","status":"200"}]}}